Pacira Pre-Announces Q4 Revenue Above Street View
8:37AM ET 1/09/2020 MT NewswiresPacira BioSciences (PCRX), a provider of innovative non-opioid pain management options, reported pre-market Thursday preliminary Q4 revenue of $122.4...
Quotes Snapshot > PCRX
Pacira Biosciences Inc PCRX:NASDAQ
Last Price$43.82NASDAQ Previous Close - Last Trade as of 3:59PM ET 1/17/20
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$43.82 (50)
Ask (Size)$43.84 (1)
Day Low / HighN/A - N/A
Volume626.5 K
Read more news Recent News
Earnings Forecast for Pacira Biosciences in 2020 Targeted Higher
12:45AM ET 1/09/2020 MT Newswires2020`s forecasted earnings estimate for Pacira Biosciences Inc (NASDAQ:PCRX, Recent Price: 43.10) for the year ending December 31, 2020 has been increased....
2020 Earnings Estimate for Pacira Biosciences Reduced
1:10AM ET 1/08/2020 MT NewswiresThe 2020 forecasted earnings estimate for Pacira Biosciences Inc's (NASDAQ:PCRX, Recent Price: 42.59) for the year ending December 31, 2020 has been...
Pacira Pharmaceuticals Reports Positive Results from Study of Exparel in Cesarean Section Patients
8:54AM ET 1/07/2020 MT NewswiresPacira Pharmaceuticals (PCRX) reported that its phase 4 study of Exparel, an injectable drug for patients undergoing a Cesarean section, achieved its...
View all Commentary and Analysis
ViacomCBS, Amazon's AWS Event And Conference Blitz (Stocks To Watch Podcast)
7:30AM ET 12/01/2019 Seeking AlphaStocks To Watch: ViacomCBS, Amazon's AWS Event And Conference Blitz
8:39AM ET 11/30/2019 Seeking AlphaTracking John Paulson's Paulson & Company Portfolio - Q3 2019 Update
8:01PM ET 11/28/2019 Seeking AlphaPacira BioSciences, Inc.'s (PCRX) CEO Dave Stack on Q3 2019 Results - Earnings Call Transcript
3:21PM ET 11/07/2019 Seeking AlphaCompany Profile
Business DescriptionPacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ. View company web site for more details
| Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.973.254.3560 |
| Number of Employees | 518 |
| Recent SEC Filing | 01/17/2020 4 |
| Chairman, Chief Executive & Operating Officer | David M. Stack |
| President | Max Reinhardt |
| Chief Financial Officer | Charles A. Reinhart |
| Vice President-Research & Development | Vladimir Kharitonov |
Company Highlights
| Price Open | $44.09 |
| Previous Close | $44.00 |
| 52 Week Range | $34.64 - 49.50 |
| Market Capitalization | $1.8 B |
| Shares Outstanding | 41.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Other | Next Earnings Announcement | 02/27/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 1.1K |
| Earnings per Share | $0.32 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | 0.55% |
| Return on Equity | 0.65% |
Analyst Ratings as of 11/04/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |